TARGET Study Demonstrates Sustained Performance and Favorable Safety Profile of the Cardiovalve TR System in High-Risk Patients with Severe Tricuspid Regurgitation
Late-breaking 6-month full cohort data presented at PCR London Valves 2026 shows durable tricuspid regurgitation reduction up to 3 years, positive…
















